CELLDEX THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.38 USD | +2.96% |
|
-4.02% | -5.98% |
| Apr. 17 | Sector Update: Health Care Stocks Mixed Wednesday Afternoon | MT |
| Apr. 17 | Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 37.27 | 693.2 | 1,803 | 2,099 | 2,169 | 2,393 | - | - |
| Enterprise Value (EV) 1 | 37.27 | 693.2 | 1,395 | 1,794 | 1,745 | 2,107 | 2,020 | 2,229 |
| P/E ratio | -0.64 x | -8.67 x | -23.6 x | -18.6 x | -13.6 x | -12.5 x | -11.2 x | -9.99 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 10.4 x | 93.5 x | 388 x | 891 x | 315 x | 707 x | 765 x | 886 x |
| EV / Revenue | 10.4 x | 93.5 x | 300 x | 761 x | 254 x | 622 x | 646 x | 825 x |
| EV / EBITDA | - | - | - | - | -11.3 x | -11.3 x | -8.44 x | - |
| EV / FCF | - | - | -22.4 x | -17 x | -16 x | -14.1 x | -10.8 x | -9.04 x |
| FCF Yield | - | - | -4.46% | -5.88% | -6.25% | -7.07% | -9.23% | -11.1% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 16,713 | 39,567 | 46,664 | 47,100 | 54,689 | 65,911 | - | - |
| Reference price 2 | 2.230 | 17.52 | 38.64 | 44.57 | 39.66 | 36.30 | 36.30 | 36.30 |
| Announcement Date | 3/26/20 | 3/29/21 | 2/28/22 | 2/28/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.573 | 7.418 | 4.651 | 2.357 | 6.883 | 3.386 | 3.129 | 2.7 |
| EBITDA 1 | - | - | - | - | -154.5 | -185.7 | -239.4 | - |
| EBIT 1 | -55.03 | -63.35 | -71.24 | -115.2 | -142 | -176.7 | -210.5 | -243.2 |
| Operating Margin | -1,540.19% | -854.06% | -1,531.78% | -4,889.01% | -2,063.66% | -5,218.99% | -6,728.95% | -9,005.56% |
| Earnings before Tax (EBT) 1 | -50.88 | -60.95 | -70.74 | -112.3 | -141.4 | -172.1 | -206 | -239.6 |
| Net income 1 | -50.88 | -59.78 | -70.51 | -112.3 | -141.4 | -170 | -202.8 | -239.8 |
| Net margin | -1,423.96% | -805.88% | -1,516.04% | -4,765.59% | -2,054.76% | -5,020.12% | -6,483.79% | -8,880.74% |
| EPS 2 | -3.510 | -2.020 | -1.640 | -2.400 | -2.920 | -2.907 | -3.241 | -3.632 |
| Free Cash Flow 1 | - | - | -62.16 | -105.6 | -109.1 | -149 | -186.5 | -246.5 |
| FCF margin | - | - | -1,336.44% | -4,478.57% | -1,585.2% | -4,400.85% | -5,961.19% | -9,129.63% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/29/21 | 2/28/22 | 2/28/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.153 | 0.333 | 0.174 | 0.163 | 0.407 | 1.613 | 0.967 | 0.268 | 1.517 | 4.132 | 0.8167 | 0.8633 | 2.28 | 0.9033 | 0.9167 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | -47.63 | -40.3 | -43.4 | - | -48.7 | -53.4 |
| EBIT 1 | -20.82 | -20.34 | -23.79 | -27.72 | -27.7 | -27.88 | -32.47 | -33.2 | -41.24 | -35.13 | -41.68 | -42.58 | - | -44.35 | -45.92 |
| Operating Margin | -13,610.46% | -6,108.11% | -13,674.14% | -17,007.36% | -6,804.91% | -1,728.77% | -3,357.91% | -12,389.93% | -2,718.46% | -850.12% | -5,103.04% | -4,931.49% | - | -4,909.61% | -5,009.98% |
| Earnings before Tax (EBT) 1 | -20.68 | -20.15 | -23.05 | -36 | -26.78 | -26.49 | -29.36 | -30.5 | -38.26 | -43.31 | -40.18 | -41.5 | - | -44.16 | -46.34 |
| Net income 1 | -20.45 | -20.15 | -23.05 | -36 | -26.78 | -26.49 | -29.36 | -30.5 | -38.26 | -43.31 | -39.68 | -40.97 | - | -43.67 | -45.87 |
| Net margin | -13,367.32% | -6,050.45% | -13,247.13% | -22,088.34% | -6,580.84% | -1,642.1% | -3,036.3% | -11,381.34% | -2,522.08% | -1,048.06% | -4,859.16% | -4,745.19% | - | -4,833.97% | -5,003.62% |
| EPS 2 | -0.4500 | -0.4300 | -0.4900 | -0.7700 | -0.5700 | -0.5600 | -0.6200 | -0.6500 | -0.8100 | -0.8300 | -0.6929 | -0.7157 | - | -0.7314 | -0.7714 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 2/28/22 | 5/5/22 | 8/8/22 | 11/9/22 | 2/28/23 | 5/4/23 | 8/8/23 | 11/2/23 | 2/26/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 408 | 305 | 424 | 285 | 373 | 164 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -62.2 | -106 | -109 | -149 | -187 | -247 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | 1.25 | - | 1.82 | 1 | 1.5 | 2 |
| Capex / Sales | - | - | 26.85% | - | 26.41% | 29.54% | 47.95% | 74.07% |
| Announcement Date | 3/26/20 | 3/29/21 | 2/28/22 | 2/28/23 | 2/26/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
36.3
USD
Average target price
70.71
USD
Spread / Average Target
+94.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.98% | 2.39B | |
| +1.96% | 42.75B | |
| +47.87% | 41.61B | |
| +12.10% | 41.34B | |
| -12.36% | 26.59B | |
| +7.98% | 25.49B | |
| -23.42% | 18.12B | |
| +30.33% | 12.24B | |
| -2.14% | 11.76B | |
| +8.22% | 11B |
- Stock Market
- Equities
- CLDX Stock
- Financials Celldex Therapeutics, Inc.
